Design of Protein-Membrane Interaction Inhibitors by Virtual Ligand Screening, Proof of Concept with the C2 Domain of Factor V

Most orally bioavailable drugs on the market are competitive inhibitors of catalytic sites, but a significant number of targets remain undrugged, because their molecular functions are believed to be inaccessible to drug-like molecules. This observation specifically applies to the development of smal...

Ausführliche Beschreibung